ライフサイエンスコーパス: classical pathway

1 uired by the alternative pathway but not the classical pathway.

2 ay of complement and is not dependent on the classical pathway.

3 by immune complexes occurs primarily by the classical pathway.

4 ific inhibition of either the alternative or classical pathway.

5 -that could mediate its nuclear import via a classical pathway.

6 eration of pathogenic antibodies through the classical pathway.

7 ctivity for the C3 and C5 convertases of the classical pathway.

8 d mechanistically distinct inhibitors of the classical pathway.

9 I/R injury is mediated via the lectin and/or classical pathway.

10 Complement C1q is the activator of the classical pathway.

11 cked by Brefeldin A, suggesting export via a classical pathway.

12 ical role for OAT1 in the functioning of the classical pathway.

13 ement is relatively inactive compared to the classical pathway.

14 onservation of the mode of activation of the classical pathway.

15 at H. felis activates complement through the classical pathway.

16 pA may inhibit complement deposition via the classical pathway.

17 the complement cascade is initiated via the classical pathway.

18 CDC," remained to be dependent on C1 and the classical pathway.

19 by delaying the synthesis of C3b through the classical pathway.

20 at binds C1q, the recognition protein of the classical pathway.

21 between components C1q, C1r, and C1s of the classical pathway.

22 ative Pathway compared with that made by the Classical Pathway.

23 lement activation via the alternative or the classical pathway.

24 rs derived from cells that had activated the Classical Pathway.

25 T3 predominantly activated complement by the classical pathway.

26 sequent activation of complement through the classical pathway.

27 y of the complement system is older than the classical pathway.

28 re effective than factor H at inhibiting the classical pathway.

29 rum (NHS) allows C. albicans to initiate the classical pathway.

30 ways, whereas pneumolysin inhibited only the classical pathway.

31 osol, where the protein is processed via the classical pathway.

32 at antibody in nonimmune serum initiates the classical pathway.

33 N-glycan conformation primarily affects the classical pathway.

34 gs can lead to complement activation via the classical pathway.

35 own to interact with other activators of the classical pathway.

36 tion of endogenous antigens by MHC-I via the classical pathway.

37 early steps of complement activation via the classical pathway.

38 nhances complement C3 deposition through the classical pathway.

39 s deposited on pneumococci primarily via the classical pathway.

40 he lectin/alternative pathways or C4b in the classical pathway.

41 nner analogous to that of C1r and C1s of the classical pathway.

42 inB2, and this depended on components in the classical pathway.

43 c UFA synthesis is distinct from that of the classical pathway.

44 natural IgM antibody and propagated via the classical pathway.

45 he more potent inhibition of only C1s of the classical pathway.

46 D, NFKB1, and TACI) selectively activate the classical pathway.

47 uld lead to activation of complement via the classical pathway.

48 s not cause injury through activation of the classical pathway.

49 in machinery and mediate signalling via 'non-classical' pathways.

50 To explore the mechanism, classical pathway-activating immune complexes were infus

51 anisms appear to be partially independent of classical pathway activation and apoptotic cell clearanc

52 C4BP, secondary to kinetically overwhelming classical pathway activation and possibly increased alte

53 nonenveloped icosahedral virus CP inhibiting classical pathway activation at C1.

54 actors demonstrated that HAstV CP suppresses classical pathway activation at the first component, C1.

55 the specific serum components necessary for classical pathway activation by F. tularensis in nonimmu

56 In contrast, classical pathway activation by high-titer antibody over

57 Ab-dependent classical pathway activation is required for complement-

58 tion was not blocked on MCP(+) cells because classical pathway activation occurred before substantial

59 Classical pathway activation was less robust than TNF-in

60 Classical pathway activation was observed in 90.5% of TM

61 he bacterium is opsonized by C3 cleavage via classical pathway activation within the alveolus, provid

62 ollowing CRP interaction and thereby inhibit classical pathway activation.

63 mation of the active C1 complex required for classical pathway activation.

64 t not SCR-4, function to selectively inhibit classical pathway activation.

65 embled by the initiating complex (C1) of the classical pathway, activation of complement component C5

66 Pooled NHS was rendered free of classical pathway activity by chelation of serum Ca2+ wi

67 age fluid contains C3 protein and functional classical pathway activity that mediates the binding of

68 , SP-A blocked the ability of C1q to restore classical pathway activity to C1q-depleted serum.

69 vation and binding of C3, characteristics of classical pathway activity, were abolished in yeast- or

70 ternative pathway activity without affecting classical pathway activity.

71 These data indicate that blockade of the classical pathway alone (C1q) is protective against perm

72 ponents that required activation of both the classical pathway and alternative pathway amplification

73 mouse embryo fibroblasts was mediated by the classical pathway and by an alternative or second pathwa

74 may help to explain how deficiencies of the classical pathway and certain pentraxins lead to impaire

75 d C1q activate complement; C1q activates the classical pathway and MBL the lectin pathway.

76 17 was responsible for the activation of the classical pathway and the observed killing of FX517 as o

77 t that was activated via the alternative and classical pathways and cleaved C3b to fragments of 68, 4

78 ent landscape of cell competition, including classical pathways and models, fitness fingerprint mecha

79 i-fHbp MAbs elicited greater C4b deposition (classical pathway) and greater bactericidal activity tha

80 easured complement activation products, C4d (classical pathway) and SC5b-9 (terminal pathway), at the

81 the complement system, predominantly via the classical pathway, and causes increased C4 activation an

82 iated C3 activation but had no effect on the classical pathway, and N-glycans in IgG were required by

83 ernative pathway as well as C4 and C2 of the classical pathway are required for complement-dependent

84 Here we have identified C1q in the classical pathway as required for activation of compleme

85 As in the classical pathway, BCR-induced ERK activation in the new

86 ree main mechanisms of action; these are the classical pathway, beta-arrestin scaffold signaling, and

87 g isotype, cannot activate complement by the classical pathway, binds more avidly to an inhibitory th

88 Both MAbs were potent activators of the classical pathway but poor facilitators of alternative p

89 tudies have confirmed the importance of many classical pathways but also revealed novel pathways.

90 A blockade of the classical pathway by absorption of putative classical pa

91 Activation of the classical pathway by immune complexes leads to the gener

92 lling of gonococcal strains that inhibit the classical pathway by recruiting C4BP.

93 ement cascade appears to be mediated via the classical pathway by the binding of C1q to ligands in AP

94 antibody against the first component of the classical pathway, C1q, were resistant to experimental B

95 n the well-defined activation complex of the classical pathway, C1qC1r(2)C1s(2), and the composition

96 f Crry and DAF in regulating alternative and classical pathway C3 activation.

97 Ps exhibited full activity against the human classical pathway C3 convertase.

98 2 to C4b which leads to the formation of the classical pathway C3 convertase.

99 by dissociating the catalytic domain of the classical pathway C3 convertase.

100 identify antimannan IgG as the initiator of classical pathway C3 deposition on C. albicans.

101 the C1 complex and prevented assembly of the classical pathway C3-convertase.

102 dy we examined the C5 cleaving properties of classical pathway C3/C5 convertase either bound to the s

103 findings differ from those reported for the classical pathway C3/C5 convertase, where only one of fo

104 are probably involved in the assembly of the classical pathway C3/C5 convertases and C4b binding to r

105 nvertases were similar to those reported for classical pathway C3/C5 convertases, studies on the abil

106 alternative pathway C3bBb compared with the classical pathway C4b2a were tested in classical pathway

107 ent origin, while a homologous member of the classical pathway (C4bpalpha) appeared later in evolutio

108 h the classical pathway C4b2a were tested in classical pathway C5 convertase (C4b2a3b) assays.

109 e propose an overall molecular model for the classical pathway C5 convertase in complex with C5, sugg

110 t the 6-9-fold greater catalytic rate of the classical pathway C5 convertase may compensate for the f

111 Pathway activity, but when measured for the Classical Pathway, C6des-748-914 was only 4-6% as effect

112 ind to and are internalized by ECs via a non-classical pathway, CAM-mediated endocytosis.

113 complement cascade via the antibody-mediated classical pathway can initiate red blood cell (RBC) dest

114 According to the "classical" pathway, CD4 cells secrete cytokines, such as

115 r and vitreous inhibited the activity of the classical pathway (CH(50)).

116 This review emphasizes that both the lack of classical pathway complement activation and excessive ac

117 appears to be at least partly independent of classical pathway complement activation by C1q.

118 n-initiated bystander and antibody-triggered classical pathway complement activation in vitro, result

119 P) that functions to inhibit alternative and classical pathway complement activation.

120 which promote C1q binding, the first step in classical pathway complement activation.

121 The classical pathway complement regulator C4b-binding prote

122 -/-) -Crry(+/+) or wild-type erythrocytes to classical pathway complement-mediated C3 deposition in v

123 pathway protein factor B (Bf(-/-)) or in the classical pathway component C4 (C4(-/-)).

124 Mice deficient in the classical pathway component complement component 4 (C4)

125 of complement activation is critical, while classical pathway components are entirely dispensable.

126 in MyoD-expressing fibroblasts deficient in classical pathway components RelA/p65, inhibitor of kapp

127 In contrast, inherited deficiency of classical pathway components, particularly C1q, is power

128 The classical pathway contributes to IC and apoptotic cell c

129 l hemolysis after forceful activation of the classical pathway could be reduced by blocking the AP.

130 ial recognition cascades that constitute the classical pathway (CP) and lectin pathway (LP).

131 inhibited the AP with minimal effect on the classical pathway (CP) and no effect on the lectin pathw

132 or decay-accelerating activity (DAA) for the classical pathway (CP) C3 and C5 convertases and, using

133 ese three mutants were also resistant to the classical pathway (CP) C5 convertase, with sensitivities

134 A promising therapeutic approach may be classical pathway (CP) inhibition at the level of early

135 onsiderable attention, little is known about classical pathway (CP) inhibition by meningococci, which

136 Activation of the classical pathway (CP) of complement is often associated

137 The classical pathway (CP) of complement may contribute to t

138 endent cytotoxicity (CDC) of B cells via the classical pathway (CP) of complement.

139 ding; enhanced C3b and factor Bb binding was classical pathway dependent.

140 Classical pathway-dependent total hemolytic activity was

141 ted by either the alternative pathway or the classical pathway, depending on the concentration of ser

142 Recently, a role has been suggested for the classical pathway during innate immunity that is activat

143 e also compared the performance of TPIEA and classical pathway enrichment analysis, and TPIEA present

144 MAbs but exhibited reduced support of early classical pathway-facilitated accumulation of C3.

145 pattern is consistent with engagement of the classical pathway followed by amplification through the

146 Exogenous GAD followed the classical pathway for antigen processing, with an absolu

147 ells lacking protein kinase C (PKC)beta, the classical pathway for BCR signaling is blocked, whereas

148 These data demonstrate the vital role of the classical pathway for innate immunity to a bacterial pat

149 However, the functional importance of the classical pathway for innate immunity to S. pneumoniae a

150 ion of STAT1, indicating divergence from the classical pathway for terminating IFN-gamma-signaling.

151 DNA in digitonin-permeabilized cells via the classical pathway for the nuclear transport of karyophil

152 this study, we report that the alternate and classical pathways for BCR signaling are differentially

153 ve, Lyn-dependent alternate pathway, and the classical pathway, for BCR signaling operate in parallel

154 The classical pathway, found throughout higher eukaryotic or

155 Although the classical pathway had been assumed to be the major pathw

156 ntification of different costimulators, this classical pathway has been shown to significantly impact

157 oradiography of radiolabeled protein; 2) for classical pathway hemolytic activity; 3) for susceptibil

158 Among the initiators of the classical pathway, IgG deposition contributes most of th

159 The classical pathway implicated in ubiquitination of the ep

160 Activation of the classical pathway in Alzheimer's disease derives from th

161 We believe there is another role for the classical pathway in maintaining immune tolerance.

162 ontaneously activated complement through the classical pathway in normal and immunoglobulin-deficient

163 tudy demonstrating an important role for the classical pathway in promoting SCI, it is likely that th

164 Btk appears to regulate directly the classical pathway in response to BAFF such that Btk-defi

165 in Candida albicans and comparison with the classical pathway in Saccharomyces cerevisiae have revea

166 ation and suggest a predominant role for the classical pathway in stimulating alloimmunity.

167 mplification via the lectin pathway than the classical pathway in the generation of C3/C5 convertases

168 ssible scenario, which parallels that of the classical pathway, in which MASP-1 and MASP-2 are found

169 luding binding to C4b-binding protein (C4BP; classical pathway inhibitor) and factor H (alternative p

170 There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) t

171 pathway plays a critical role in amplifying classical pathway initiated complement activation.

172 f the sites for early C3 binding showed that classical pathway initiation led to immediate, synchrono

173 osition of C3 that was characteristic of the classical pathway initiation was reciprocally cross-abso

174 In the absence of classical pathway initiation, the early cellular sites f

175 G (IgG) in normal human serum (NHS) mediates classical pathway initiation.

176 urring anti-C. albicans immunoglobulin C. in classical pathway initiation.

177 classical pathway by absorption of putative classical pathway initiators or by chelation of calcium

178 ransglutaminase 2 (TG2) is secreted by a non-classical pathway into the extracellular space, where it

179 The classical pathway involved the IkappaB kinase (IKK)beta-

180 he lower CPE dose was shown to proceed via a classical pathway involving mitochondrial membrane depol

181 on of NF-kappaB is partially mediated by the classical pathway involving the interaction between the

182 ntation through mechanisms distinct from the classical pathways involving H-2DM molecules.

183 Because the classical pathway is an important and specific mediator

184 ay for BCR signaling is blocked, whereas the classical pathway is little affected.

185 The classical pathway is more efficient at inducing CD8 cell

186 complement, and recent data suggest that the classical pathway is required for complement factor C3 d

187 activation through the alternative, but not classical, pathway is required to initiate antibody-indu

188 aracterized import pathway, often termed the classical pathway, is utilized by many basic-type (lysin

189 gG1-Lec 1 was deficient in activation of the classical pathway, it had a superior capacity to activat

190 ve the activation of fetal complement by the classical pathway leading to the formation of membrane a

191 three pathways of complement activation, the classical pathway, lectin pathway, and alternative pathw

192 fold or if Mg(2+)-EGTA was used to block the classical pathway, MCP efficiently inhibited C3b deposit

193 Thus, for the classical pathway, MCP is the cofactor for C4b cleavage

194 hrocyte lysis by both the reactive lysis and classical pathway mechanisms.

195 were operative, group II MAbs induced early classical pathway-mediated binding of C3 but reduced the

196 pecific for the APC C3/C5 convertase because classical pathway-mediated hemolysis is unaffected by 3E

197 , and both C4 molecules equally restored the classical pathway-mediated hemolytic activity of serum d

198 hritis, DAF serves as the primary barrier to classical pathway-mediated injury, while CD59 limits con

199 forms also provided enhanced protection in a classical pathway-mediated system and cleaved cell-bound

200 greater deposition of C1q and thus increased classical-pathway-mediated C3 deposition.

201 While the classical pathway mediating this response is via mTOR in

202 From this, it follows that the classical pathway might be needed in order to kick-start

203 e duplication that gave rise to the earliest classical pathway molecules.

204 M and IgG that activate the C system via the classical pathway, normal membrane regulators of C (e.g.

205 se (Cyp7a1), the rate-limiting enzyme in the classical pathway of bile acid synthesis, has been impli

206 rior functional data suggest that C1s in the classical pathway of complement activated by, e.g., anti

207 These studies show that BrkA inhibits the classical pathway of complement activation and prevents

208 a Ca(2+)-dependent manner and augmented the classical pathway of complement activation but protected

209 d prevented erythrocyte lysis by controlling classical pathway of complement activation by cleaving t

210 t recombinant PepO specifically inhibits the classical pathway of complement activation in both hemol

211 dies reveal an important role for C1q in the classical pathway of complement activation in the develo

212 component C1, the complex that initiates the classical pathway of complement activation, is a 790-kDa

213 C1, the first protein of the classical pathway of complement activation, is a calcium

214 C1q is the recognition component of the classical pathway of complement activation.

215 anifest hyperacute rejection mediated by the classical pathway of complement activation.

216 tivation of the innate immune system via the classical pathway of complement activation.

217 r membrane porin (Por) molecules to bind the classical pathway of complement down-regulatory protein

218 man fetal neurons activate spontaneously the classical pathway of complement in an antibody-independe

219 tribution of CRP's ability of activating the classical pathway of complement in the protection of mic

220 odies with limited abilities to activate the classical pathway of complement in vitro have been impli

221 The classical pathway of complement is activated upon bindin

222 The classical pathway of complement is crucial to the immune

223 Results demonstrated that the classical pathway of complement mediated serum neutraliz

224 bs may be capable of directly activating the classical pathway of complement under certain circumstan

225 In situ activation of the classical pathway of complement was evident by depositio

226 Sle1c Crry and their ability to regulate the classical pathway of complement were not significantly d

227 natural IgM and the early components of the classical pathway of complement work in concert to neutr

228 We found that glomerular IgM activates the classical pathway of complement, but it does not cause s

229 ce binding of IgM, a potent activator of the classical pathway of complement, to both Rd and NT127.

230 e protease, C1r, initiates activation of the classical pathway of complement, which is a crucial inna

231 -induced inflammation can be mediated by the classical pathway of complement.

232 92 was delayed, suggesting regulation of the classical pathway of complement.

233 ndependent of CRP-mediated activation of the classical pathway of complement.

234 important role for natural antibody and the classical pathway of complement.

235 ween starter molecules of hemostasis and the classical pathway of complement.

236 mplement C1 that initiates activation of the classical pathway of complement.

237 ally specific natural IgM that activates the classical pathway of complement.

238 resulting from enhanced serum killing by the classical pathway of complement.

239 are sequentially activated and initiate the classical pathway of complement.

240 use natural antibodies and activation of the classical pathway of complement.

241 and antibody-antigen complexes [6,7] in the classical pathway of complement.

242 isoforms preferentially protect against the classical pathway of complement.

243 m the conformational model suggested for the classical pathway of complement.

244 s in increased sensitivity to killing by the classical pathway of complement.

245 ng that blocking resulted from inhibition of classical pathway of complement.

246 preserving important immune functions of the classical pathway of complement.

247 s inhibits killing by the antibody-dependent classical pathway of complement; however, susceptibility

248 asm and is presented to CD8+ T cells via the classical pathway of MHC class I presentation.

249 of quiescent fibroblast does not induce the classical pathway of NF-kappaB activation through Ikappa

250 the early components (C1, C4, or C2) of the classical pathway of the complement cascade is one of th

251 C2, yet play a role in both alternative and classical pathways of complement activation.

252 eumoniae, thereby reducing activation of the classical pathway on the bacterial surface.

253 ns at the level of the second enzyme of this classical pathway or of the noninducible system had no s

254 actor 4 (C4-/-), a critical component of the classical pathway, or factor B (fB-/-), an essential pro

255 Furthermore, the classical pathway, partially targeted by the binding of

256 Together, these data suggest that the classical pathway plays a major role in complement activ

257 hysiological action of the early part of the classical pathway protects against the development of SL

258 ically have autoantibodies to the complement classical pathway protein C1q.

259 er hand, homozygous deficiency of any of the classical pathway proteins is strongly associated with t

260 Furthermore, mice deficient in classical pathway proteins were not protected from injur

261 de sialylation of N. gonorrhoeae resulted in classical pathway regulation as evidenced by decreased C

262 ypass the requirements for engagement of the classical pathway remain to be defined but do not appear

263 ured to examine activation of the lectin and classical pathways, respectively.

264 rowing evidence that proteins fold through a classical pathway sequence of native-like intermediates

265 plement activation occurred primarily by the classical pathway, since a deficiency in the C4 componen

266 reperfusion injury compared with wild-type, classical pathway-specific C1q-deficient mice, or MBL-de

267 beta-Glucan absorption of NHS abolished the classical pathway, suggesting that cell wall beta-glucan

268 d to the capacity of the Abs to activate the classical pathway, suggesting that the orientation of th

269 ses suggest that SGSs are secreted via a non-classical pathway that involves cleavage into a 300-kDa

270 ting system for novel cell biology even with classical pathways that have been studied extensively in

271 However, unlike the classical pathway, the alternative pathway is also depen

272 In the classical pathway, the ER binds directly to an estrogen

273 Although IgG can activate the classical pathway, there also is evidence that alternati

274 ent surface deposition of complement via the classical pathway, thereby contributing to the ability o

275 scussed in terms of the energy landscape and classical pathway time regimes of folding, for which the

276 ed significantly below basal levels, whereas classical pathway titers were unchanged.

277 The proposed model for ClyA represents a non-classical pathway to attack eukaryotic host cells.

278 Blocking either the classical pathway (treatments with EGTA-Mg2+ or soluble

279 factor-induced AP complement activation, and classical pathway-triggered AP complement amplification

280 ogens or altered self through the lectin and classical pathways, two of the three well-established ac

281 e borders, which are usually assigned in the classical pathway view of molecular events (e.g. signal

282 her antibody-mediated activation through the classical pathway was a major mechanism for complement a

283 n serum in untreated animals showed that the classical pathway was activated during the first 2 hours

284 When the classical pathway was blocked, group II and III MAbs mar

285 ent strain or a complemented mutant when the classical pathway was inactivated by depleting NHS of C1

286 , PspA also inhibited C3 deposition when the classical pathway was initiated by antibodies to capsula

287 The classical pathway was required in vitro, whereas complem

288 In nonimmune mouse serum, the classical pathway was the dominant activation pathway tr

289 alternative complement pathway, but not the classical pathway, was described in 2009.

290 To better understand the evolution of the classical pathway, we have evaluated the degree of funct

291 strain rates of quantal neurotransmission if classical pathways were solely responsible for vesicle r

292 C4, the complement components unique to the classical pathway, were not detected in the diabetic ret

293 Binding of LDL to CR1 is mediated via the classical pathway, whereas binding of acLDL is mediated

294 pneumoniae bound by C3 depends mainly on the classical pathway, whereas the intensity of C3 binding d

295 leted serum through both the alternative and classical pathways; whether Bf-1 possess similar activit

296 e possibility of its being secreted by a non-classical pathway, which is not clearly understood.

297 more familiar but evolutionarily more recent classical pathway, which is triggered by antibody bindin

298 on proceeds approximately 70-75% through the classical pathway while only approximately 25-30% seems

299 ent C1q and activation of complement via the classical pathway without any concomitant engagement of

300 In the absence of the classical pathway, yeast cells bound 80% of the maximum